NCT02962492 - An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes | Biotech Hunter

Enrollment

70

Participants

Timeline

Start Date

November 1, 2016

Primary Completion Date

February 1, 2021

Study Completion Date

October 24, 2021

Conditions

Evaluate Ketogenic Stress

Interventions

DRUG

Exenatide/Exenatide extended release

Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks

DRUG

Dapagliflozin

Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks

DRUG

Placebo

Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks

Trial Locations (1)

14221

Diabetes and Endocrinology Research Center of WNY, Williamsville